Combined PEG liposomal doxorubicin and gemcitabine are active and have acceptable toxicity in patients with platinum-refractory and -resistant ovarian cancer after previous platinum–taxane therapy: A phase II Austrian AGO study
Authors:
- E. PetruEPE. Petru
- L. Angleitner-BoubenizekLAL. Angleitner-Boubenizek
- A. ReinthallerARA. Reinthaller
- M. DeiblMDM. Deibl
- A.G. ZeimetAZA.G. Zeimet
- B. VolggerBVB. Volgger
- A. StempflASA. Stempfl
- C. MarthCMC. Marth
- 1 August 2006
- journal article
- research article
- Published by Elsevier in Gynecologic Oncology
- Vol. 102 (2) , 226-229
Abstract
No abstract availableKeywords
This publication has 6 references indexed in Scilit:
- Survival following the documentation of platinum and taxane resistance in ovarian cancer: a single institution experience involving multiple phase 2 clinical trialsGynecologic Oncology, 2004
- Phase II study of liposomal doxorubicin and gemcitabine in the salvage treatment of ovarian cancerBritish Journal of Cancer, 2003
- Phase II Study of Pegylated Liposomal Doxorubicin in Combination With Gemcitabine in Patients With Metastatic Breast CancerJournal of Clinical Oncology, 2003
- Does Palliative Chemotherapy Palliate? Evaluation of Expectations, Outcomes, and Costs in Women Receiving Chemotherapy for Advanced Ovarian CancerJournal of Clinical Oncology, 2001
- Schedule-dependent interaction of doxorubicin, paclitaxel and gemcitabine in human breast cancer cell linesInternational Journal of Cancer, 1999
- Tumour markersAnnals of Oncology, 1993